中枢神経系（CNS）バイオマーカー：技術と世界市場

中枢神経系（CNS）バイオマーカーの世界市場は、2025年の76億ドルから2030年末までに138億ドルに成長すると予測されており、2025年から2030年までの年平均成長率（CAGR）は12.6%に達するとBCC Research では予測しています。

レポートの内容

•  141のデータ表と44の追加表
•  中枢神経系（CNS）バイオマーカーの世界市場に関する最新の概要と分析
•  2022年から2024年までの過去の収益データ、2025年の推定値、2030年までの予測（2030年までのCAGR予測を含む）など、世界市場の動向を詳細に分析
•  ポーターの5フォースモデルと業界サプライチェーン分析を包括的に検討し、市場におけるミクロおよびマクロ環境要因の両方を考慮した市場機会の分析
•  世界市場に影響を与える市場促進要因、阻害要因、その他の要因の説明
•  アルツハイマー病、うつ病、パーキンソン病、多発性硬化症などのCNS疾患セグメント、罹患率、治療におけるギャップについての考察
•  進化する技術、現在および将来の市場可能性、研究開発活動、成長戦略、規制枠組み、償還シナリオに関する解説
•  概要持続可能性の動向とESGの発展、特に消費者の意識と主要企業の取り組みに焦点を当てた分析。
•  独自の技術、合併・買収、合弁事業、その他の戦略的提携を通じて、この需要を満たすのに最適な企業を特定。
•  Thermo Fisher Scientific Inc.、F. Hoffmann-La Roche Ltd.、Siemens Healthineers、Abbott、Bio-Rad Laboratories Inc.など、世界をリードする企業のプロファイル。

Report Highlights

The global market for central nervous system (CNS) biomarkers is estimated to grow from $7.6 billion in 2025 to reach $13.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 through 2030.

Report Includes

• 141 data tables and 44 additional tables
• An up-to-date overview and analysis of the global market for central nervous system (CNS) biomarkers
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030, including projections of CAGRs through 2030
• Analysis of market opportunities with a holistic review of Porter’s Five Forces model and industry supply chain analysis, considering both micro- and macro-environmental factors prevailing in the market
• Explanation of market drivers, restraints and other forces impacting the global market
• Discussion of CNS disease segments, prevalence and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, etc.
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the practices of leading companies
• Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
• Profiles of the leading global companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Abbott and Bio-Rad Laboratories Inc.

Report Scope

The report examines and segments the global central nervous system (CNS) biomarkers market by disease, application, technology and biomarker type. It also provides insights into emerging trends and potential growth drivers. The report focuses on Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease and others. By application, it examines drug discovery and development, clinical diagnostics and personalized medicine. By technology, proteomics, molecular imaging and genomics are reviewed. Finally, biomarker types such as amyloid-beta, tau protein and others are considered.

The report also provides an inclusive regional analysis covering North America, Europe, Asia-Pacific, South America and the Middle East and Africa. It evaluates the impact of AI adoption on the CNS biomarkers industry and market dynamics, including drivers, challenges and emerging trends, while highlighting innovations in product and performance enhancements. The study concludes with an analysis of major market participants and their offerings.

Global revenue ($ million) for the base year of 2024, estimates for 2025 and data for the forecast period 2025 through 2030 are also part of the report.

Table of Contents

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Current Market Overview
Outlook
Analysis of Macroeconomic Factors
Impact of U.S. Tariffs on the Market
Impact of the Ukraine-Russia War
Global Economic Stability and Supply Chains
Public and Private R&D Investment
Healthcare Expenditure and Economic Growth
Aging Population and Disease Burden
Porter’s Five Forces Analysis
Bargaining Power of Buyers: Moderate to High
Bargaining Power of Suppliers: High
Potential for New Entrants: Moderate to Low
Threat of Substitute: Moderate
Competition in the Industry: High
Chapter 3 Market Dynamics
Market Dynamics Snapshot
Market Drivers
Prevalence of Neurological Disorders
Advances in Diagnostic Technologies and Research
Focus on Early Detection and Personalized Medicine
Market Restraints
High Cost of Advanced Diagnostic Assays
Regulatory and Validation Challenges
Limited Awareness and Adoption Among Healthcare Providers
Market Opportunities
Growth in Neurodegenerative Disease Research
Expansion of Early Diagnosis and Screening Programs
Integration with Personalized Medicine
Chapter 4 Regulatory Landscape
Regulatory Framework
U.S.
Europe
India
Australia
Japan
Chapter 5 Emerging Technologies and Patent Analysis
Overview
Emerging Technologies
High-Resolution Mass Spectrometry
Next-Generation Sequencing
Multiplexed Immunoassays
Single-Cell RNA Sequencing
Patent Analysis
Key Takeaways
Patents by Year
Patents by Leading Jurisdiction
Patents by Applicants
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global CNS Biomarkers Market, by Disease
Key Takeaways
Alzheimer’s Disease
MS, ALS and FTD
Parkinson’s Disease
Others
Global CNS Biomarkers Market, by Application
Key Takeaways
Drug Discovery and Development
Clinical Diagnostics
Personalized Medicine
Global CNS Biomarkers Market, by Technology
Key Takeaways
Proteomics
Molecular Imaging
Genomics
Global CNS Biomarkers Market, by Biomarker Type
Key Takeaways
Amyloid-Beta
Tau Protein
Others
Geographic Breakdown
Global CNS Biomarkers Market, by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America
Chapter 7 Competitive Intelligence
Industry Structure
Company Market Share Analysis
Strategic Analysis
Chapter 8 Sustainability in the CNS Biomarkers Market: An ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives in the CNS Biomarkers Industry
Concluding Remarks
Chapter 9 Appendix
Methodology
Abbreviations
Company Profiles
ABBOTT
BIOMERIEUX
BIO-RAD LABORATORIES INC.
C2N DIAGNOSTICS
F. HOFFMANN-LA ROCHE LTD.
FUJIREBIO
LABCORP
LILLY USA LLC.
MERCK KGAA
QUANTERIX
QUEST DIAGNOSTICS INC.
REVVITY
SIEMENS HEALTHINEERS AG
SYSMEX CORP.
THERMO FISHER SCIENTIFIC INC.
Emerging Start-ups/Market Disruptors

List of Tables

Summary Table : Global Market for CNS Biomarkers, by Region, Through 2030
Table 1 : Patents Granted for CNS Biomarkers, by Year, 2022–2025
Table 2 : Patents Granted for CNS Biomarkers, by Top Jurisdiction, 2022–2025
Table 3 : Patents Granted for CNS Biomarkers, by Applicants, 2022–2025
Table 4 : Global Market for CNS Biomarkers, by Disease, Through 2030
Table 5 : Global Market for Alzheimer’s Disease in CNS Biomarkers, by Region, Through 2030
Table 6 : Global Market for MS, ALS and FTD in CNS Biomarkers, by Region, Through 2030
Table 7 : Global Market for Parkinson’s Disease in CNS Biomarkers, by Region, Through 2030
Table 8 : Global Market for Other Diseases in CNS Biomarkers, by Region, Through 2030
Table 9 : Global Market for CNS Biomarkers, by Application, Through 2030
Table 10 : Global Market for CNS Biomarkers for Drug Discovery and Development, by Region, Through 2030
Table 11 : Global Market for CNS Biomarkers for Clinical Diagnostics, by Region, Through 2030
Table 12 : Global Market for CNS Biomarkers for Personalized Medicine, by Region, Through 2030
Table 13 : Global Market for CNS Biomarkers, by Technology, Through 2030
Table 14 : Global Market for Proteomic Biomarkers, by Region, Through 2030
Table 15 : Global Market for Molecular Imaging in CNS Biomarkers, by Region, Through 2030
Table 16 : Global Market for Genomic Biomarkers, by Region, Through 2030
Table 17 : Global Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 18 : Global Market for Amyloid-Beta Biomarkers, by Region, Through 2030
Table 19 : Global Market for Tau Protein Biomarkers, by Region, Through 2030
Table 20 : Global Market for Other CNS Biomarkers, by Region, Through 2030
Table 21 : Global Market for CNS Biomarkers, by Region, Through 2030
Table 22 : North American Market for CNS Biomarkers, by Disease, Through 2030
Table 23 : North American Market for CNS Biomarkers, by Application, Through 2030
Table 24 : North American Market for CNS Biomarkers, by Technology, Through 2030
Table 25 : North American Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 26 : North American Market for CNS Biomarkers, by Country, Through 2030
Table 27 : U.S. Market for CNS Biomarkers, by Disease, Through 2030
Table 28 : U.S. Market for CNS Biomarkers, by Application, Through 2030
Table 29 : U.S. Market for CNS Biomarkers, by Technology, Through 2030
Table 30 : U.S. Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 31 : Canadian Market for CNS Biomarkers, by Disease, Through 2030
Table 32 : Canadian Market for CNS Biomarkers, by Application, Through 2030
Table 33 : Canadian Market for CNS Biomarkers, by Technology, Through 2030
Table 34 : Canadian Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 35 : Mexican Market for CNS Biomarkers, by Disease, Through 2030
Table 36 : Mexican Market for CNS Biomarkers, by Application, Through 2030
Table 37 : Mexican Market for CNS Biomarkers, by Technology, Through 2030
Table 38 : Mexican Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 39 : Prevalence of Dementia in Europe, by Age Group and Sex, 2025
Table 40 : European Market for CNS Biomarkers, by Disease, Through 2030
Table 41 : European Market for CNS Biomarkers, by Application, Through 2030
Table 42 : European Market for CNS Biomarkers, by Technology, Through 2030
Table 43 : European Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 44 : European Market for CNS Biomarkers, by Country, Through 2030
Table 45 : German Market for CNS Biomarkers, by Disease, Through 2030
Table 46 : German Market for CNS Biomarkers, by Application, Through 2030
Table 47 : German Market for CNS Biomarkers, by Technology, Through 2030
Table 48 : German Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 49 : U.K. Market for CNS Biomarkers, by Disease, Through 2030
Table 50 : U.K. Market for CNS Biomarkers, by Application, Through 2030
Table 51 : U.K. Market for CNS Biomarkers, by Technology, Through 2030
Table 52 : U.K. Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 53 : French Market for CNS Biomarkers, by Disease, Through 2030
Table 54 : French Market for CNS Biomarkers, by Application, Through 2030
Table 55 : French Market for CNS Biomarkers, by Technology, Through 2030
Table 56 : French Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 57 : Italian Market for CNS Biomarkers, by Disease, Through 2030
Table 58 : Italian Market for CNS Biomarkers, by Application, Through 2030
Table 59 : Italian Market for CNS Biomarkers, by Technology, Through 2030
Table 60 : Italian Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 61 : Spanish Market for CNS Biomarkers, by Disease, Through 2030
Table 62 : Spanish Market for CNS Biomarkers, by Application, Through 2030
Table 63 : Spanish Market for CNS Biomarkers, by Technology, Through 2030
Table 64 : Spanish Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 65 : Rest of Europe Market for CNS Biomarkers, by Disease, Through 2030
Table 66 : Rest of Europe Market for CNS Biomarkers, by Application, Through 2030
Table 67 : Rest of Europe Market for CNS Biomarkers, by Technology, Through 2030
Table 68 : Rest of Europe Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 69 : Asia-Pacific Market for CNS Biomarkers, by Disease, Through 2030
Table 70 : Asia-Pacific Market for CNS Biomarkers, by Application, Through 2030
Table 71 : Asia-Pacific Market for CNS Biomarkers, by Technology, Through 2030
Table 72 : Asia-Pacific Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 73 : Asia-Pacific Market for CNS Biomarkers, by Country, Through 2030
Table 74 : Chinese Market for CNS Biomarkers, by Disease, Through 2030
Table 75 : Chinese Market for CNS Biomarkers, by Application, Through 2030
Table 76 : Chinese Market for CNS Biomarkers, by Technology, Through 2030
Table 77 : Chinese Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 78 : Japanese Market for CNS Biomarkers, by Disease, Through 2030
Table 79 : Japanese Market for CNS Biomarkers, by Application, Through 2030
Table 80 : Japanese Market for CNS Biomarkers, by Technology, Through 2030
Table 81 : Japanese Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 82 : Indian Market for CNS Biomarkers, by Disease, Through 2030
Table 83 : Indian Market for CNS Biomarkers, by Application, Through 2030
Table 84 : Indian Market for CNS Biomarkers, by Technology, Through 2030
Table 85 : Indian Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 86 : South Korean Market for CNS Biomarkers, by Disease, Through 2030
Table 87 : South Korean Market for CNS Biomarkers, by Application, Through 2030
Table 88 : South Korean Market for CNS Biomarkers, by Technology, Through 2030
Table 89 : South Korean Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 90 : Australian Market for CNS Biomarkers, by Disease, Through 2030
Table 91 : Australian Market for CNS Biomarkers, by Application, Through 2030
Table 92 : Australian Market for CNS Biomarkers, by Technology, Through 2030
Table 93 : Australian Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 94 : Rest of Asia-Pacific Market for CNS Biomarkers, by Disease, Through 2030
Table 95 : Rest of Asia-Pacific Market for CNS Biomarkers, by Application, Through 2030
Table 96 : Rest of Asia-Pacific Market for CNS Biomarkers, by Technology, Through 2030
Table 97 : Rest of Asia-Pacific Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 98 : MEA Market for CNS Biomarkers, by Disease, Through 2030
Table 99 : MEA Market for CNS Biomarkers, by Application, Through 2030
Table 100 : MEA Market for CNS Biomarkers, by Technology, Through 2030
Table 101 : MEA Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 102 : MEA Market for CNS Biomarkers, by Country, Through 2030
Table 103 : Middle East Market for CNS Biomarkers, by Disease, Through 2030
Table 104 : Middle East Market for CNS Biomarkers, by Application, Through 2030
Table 105 : Middle East Market for CNS Biomarkers, by Technology, Through 2030
Table 106 : Middle East Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 107 : African Market for CNS Biomarkers, by Disease, Through 2030
Table 108 : African Market for CNS Biomarkers, by Application, Through 2030
Table 109 : African Market for CNS Biomarkers, by Technology, Through 2030
Table 110 : African Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 111 : South American Market for CNS Biomarkers, by Disease, Through 2030
Table 112 : South American Market for CNS Biomarkers, by Application, Through 2030
Table 113 : South American Market for CNS Biomarkers, by Technology, Through 2030
Table 114 : South American Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 115 : South American Market for CNS Biomarkers, by Country, Through 2030
Table 116 : Brazilian Market for CNS Biomarkers, by Disease, Through 2030
Table 117 : Brazilian Market for CNS Biomarkers, by Application, Through 2030
Table 118 : Brazilian Market for CNS Biomarkers, by Technology, Through 2030
Table 119 : Brazilian Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 120 : Argentine Market for CNS Biomarkers, by Disease, Through 2030
Table 121 : Argentine Market for CNS Biomarkers, by Application, Through 2030
Table 122 : Argentine Market for CNS Biomarkers, by Technology, Through 2030
Table 123 : Argentine Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 124 : Rest of South America Market for CNS Biomarkers, by Disease, Through 2030
Table 125 : Rest of South America Market for CNS Biomarkers, by Application, Through 2030
Table 126 : Rest of South America Market for CNS Biomarkers, by Technology, Through 2030
Table 127 : Rest of South America Market for CNS Biomarkers, by Biomarker Type,Through 2030
Table 128 : Strategic Initiatives for CNS Biomarkers Market, 2024 and 2025
Table 129 : Abbreviations Used in the Global CNS Biomarkers Market Report
Table 130 : Abbott: Company Snapshot
Table 131 : Abbott: Financial Performance, FY 2023 and 2024
Table 132 : Abbott: Product Portfolio
Table 133 : Abbott: News/Key Developments, 2023 and 2024
Table 134 : bioMérieux: Company Snapshot
Table 135 : bioMérieux: Financial Performance, FY 2023 and 2024
Table 136 : bioMérieux: Product Portfolio
Table 137 : bioMérieux: News/Key Developments, 2023 and 2024
Table 138 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 139 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
Table 140 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 141 : Bio-Rad Laboratories Inc.: News/Key Developments, 2024 and 2025
Table 142 : C2N Diagnostics: Company Snapshot
Table 143 : C2N Diagnostics: Product Portfolio
Table 144 : C2N Diagnostics: News/Key Developments, 2022-2025
Table 145 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 146 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 147 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 148 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 149 : Fujirebio: Company Snapshot
Table 150 : Fujirebio: Product Portfolio
Table 151 : Fujirebio: News/Key Developments, 2023-2025
Table 152 : Labcorp: Company Snapshot
Table 153 : Labcorp: Financial Performance, FY 2023 and 2024
Table 154 : Labcorp: Product Portfolio
Table 155 : Labcorp: News/Key Developments, 2024 and 2025
Table 156 : Lilly USA LLC.: Company Snapshot
Table 157 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 158 : Lilly USA LLC.: Product Portfolio
Table 159 : Merck KGaA: Company Snapshot
Table 160 : Merck KGaA: Financial Performance, FY 2023 and 2024
Table 161 : Merck KGaA: Product Portfolio
Table 162 : Merck KGaA: News/Key Developments, 2024
Table 163 : Quanterix: Company Snapshot
Table 164 : Quanterix: Financial Performance, FY 2023 and 2024
Table 165 : Quanterix: Product Portfolio
Table 166 : Quanterix: News/Key Developments, 2025
Table 167 : Quest Diagnostics Inc.: Company Snapshot
Table 168 : Quest Diagnostics Inc.: Financial Performance, FY 2023 and 2024
Table 169 : Quest Diagnostics Inc.: Product Portfolio
Table 170 : Revvity: Company Snapshot
Table 171 : Revvity: Financial Performance, FY 2023 and 2024
Table 172 : Revvity: Product Portfolio
Table 173 : Siemens Healthineers AG: Company Snapshot
Table 174 : Siemens Healthineers AG: Financial Performance, FY 2023 and 2024
Table 175 : Siemens Healthineers AG: Product Portfolio
Table 176 : Siemens Healthineers AG: News/Key Developments, 2024 and 2025
Table 177 : Sysmex Corp.: Company Snapshot
Table 178 : Sysmex Corp.: Financial Performance, FY 2023 and 2024
Table 179 : Sysmex Corp.: Product Portfolio
Table 180 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 181 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 182 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 183 : Thermo Fisher Scientific Inc.: News/Key Developments, 2025
Table 184 : List of a Few Emerging Startups

List of Figures

Summary Figure : Global Market Share for CNS Biomarkers, by Region, 2024
Figure 1 : Porter’s Five Forces Analysis: CNS Biomarkers Market
Figure 2 : Market Dynamics of CNS Biomarkers
Figure 3 : Global Market Share for CNS Biomarkers, by Disease, 2024
Figure 4 : Global Market Share for Alzheimer’s Disease in CNS Biomarkers, by Region, 2024
Figure 5 : Global Market Share for MS, ALS and FTD in CNS Biomarkers, by Region, 2024
Figure 6 : Global Market Share for Parkinson’s Disease in CNS Biomarkers, by Region, 2024
Figure 7 : Global Market Share for Other Diseases in CNS Biomarkers, by Region, 2024
Figure 8 : Global Market Share for CNS Biomarkers, by Application, 2024
Figure 9 : Global Market Share for CNS Biomarkers for Drug Discovery and Development, by Region, 2024
Figure 10 : Global Market Share for CNS Biomarkers for Clinical Diagnostics, by Region, 2024
Figure 11 : Global Market Share for CNS Biomarkers for Personalized Medicine, by Region, 2024
Figure 12 : Global Market Share for CNS Biomarkers, by Technology, 2024
Figure 13 : Global Market Share for Proteomic Biomarkers, by Region, 2024
Figure 14 : Global Market Share for Molecular Imaging in CNS Biomarkers, by Region, 2024
Figure 15 : Global Market Share for Genomic Biomarkers, by Region, 2024
Figure 16 : Global Market Share for CNS Biomarkers, by Biomarker Type, 2024
Figure 17 : Global Market Share for Amyloid-beta Biomarkers, by Region, 2024
Figure 18 : Global Market Share for Tau Protein Biomarkers, by Region, 2024
Figure 19 : Global Market Share for Other CNS Biomarkers, by Region, 2024
Figure 20 : Global Market Share for CNS Biomarkers, by Region, 2024
Figure 21 : North American Market Share for CNS Biomarkers, by Country, 2024
Figure 22 : European Market Share for CNS Biomarkers, by Country, 2024
Figure 23 : Asia-Pacific Market Share for CNS Biomarkers, by Country, 2024
Figure 24 : MEA Market Share for CNS Biomarkers, by Country, 2024
Figure 25 : South American Market Share for CNS Biomarkers, by Country, 2024
Figure 26 : Global Market Share for CNS Biomarkers, by Leading Companies, FY 2024
Figure 27 : Abbott: Revenue Share, by Business Unit, FY 2024
Figure 28 : Abbott: Revenue Share, by Country/Region, FY 2024
Figure 29 : bioMérieux: Revenue Share, by Business Unit, FY 2024
Figure 30 : bioMérieux: Revenue Share, by Country/Region, FY 2024
Figure 31 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
Figure 32 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
Figure 33 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 34 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 35 : Labcorp: Revenue Share, by Business Unit, FY 2024
Figure 36 : Labcorp: Revenue Share, by Country/Region, FY 2024
Figure 37 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
Figure 38 : Merck KGaA: Revenue Share, by Business Unit, FY 2024
Figure 39 : Merck KGaA: Revenue Share, by Country/Region, FY 2024
Figure 40 : Quanterix: Revenue Share, by Business Unit, FY 2024
Figure 41 : Quanterix: Revenue Share, by Country/Region, FY 2024
Figure 42 : Quest Diagnostics Inc.: Revenue Share, by Business Unit, FY 2024
Figure 43 : Revvity: Revenue Share, by Business Unit, FY 2024
Figure 44 : Revvity: Revenue Share, by Country/Region, FY 2024
Figure 45 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024
Figure 46 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024
Figure 47 : Sysmex Corp.: Revenue Share, by Country/Region, FY 2024
Figure 48 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2024
Figure 49 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2024